Pulmonx outlines 2026 revenue target of $90M-$92M with cost realignment and renewed U.S. sales focus [Seeking Alpha]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Seeking Alpha
CEO Glendon French noted, “During the past few months, Derrick and I have taken a deliberate bottom-up approach to assess the business, building on what's working, addressing what isn't and better aligning our spending Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights Management realigned the cost structure, prioritized high-return programs, restructured U.S. sales oversight, refined incentives, and implemented direct CEO sales supervision to correct sales force and operational missteps. Pulmonx projects 2026 revenue of $90-92 million, expects a return to year-over-year growth later in the year, maintains gross margin guidance of around 75%, and anticipates progress via U.S. hiring ramp and resumed China shipments. Key risks include sales force turnover, misaligned incentives, China certificate delays, and clinical trial pace; mitigations involve cost
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx (LUNG) had its price target lowered by Canaccord Genuity Group Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Pulmonx (LUNG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Sales Force ... [Yahoo! Finance]Yahoo! Finance
- Pulmonx Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Pulmonx (LUNG) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
LUNG
Earnings
- 3/4/26 - Beat
LUNG
Analyst Actions
- 3/5/26 - Canaccord Genuity
LUNG
Sec Filings
- 3/10/26 - Form S-8
- 3/10/26 - Form 10-K
- 3/9/26 - Form SCHEDULE
- LUNG's page on the SEC website